[go: up one dir, main page]

AR035001A1 - Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento - Google Patents

Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento

Info

Publication number
AR035001A1
AR035001A1 ARP990104054A ARP990104054A AR035001A1 AR 035001 A1 AR035001 A1 AR 035001A1 AR P990104054 A ARP990104054 A AR P990104054A AR P990104054 A ARP990104054 A AR P990104054A AR 035001 A1 AR035001 A1 AR 035001A1
Authority
AR
Argentina
Prior art keywords
lipase inhibitor
prepare
pharmaceutical compositions
gastrointestinal lipase
compounds
Prior art date
Application number
ARP990104054A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035001A1 publication Critical patent/AR035001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Jellies, Jams, And Syrups (AREA)

Abstract

Composiciones farmacéuticas de administración oral que contienen un inhibidor de lipasa gastrointestinal, uno (o más) aditivo(s) del grupo que consiste en espesantes y emulsionantes de baja digestibilidad, poca fermentabilidad, hidrófilos y/o hidrocoloides de grado alimenticio, y excipientes auxiliares; el comprimido masticable que lo comprende y el uso de uno (o más) compuesto(s) del grupo consistente en espesantes y emulsionante de baja digestibilidad, poca fermentabilidad, hidrófilos y/o hidrocoloides de grado alimenticio, que es para preparar un medicamento para el tratamiento o prevención del síndrome de pérdidas anales de aceite que se producen ocasionalmente tras la administración de un inhibidor de lipasa gastrointestinal, tal como orlistat, o tras la ingestión de alimentos que contienen grasas o aceites poco absorbibles o no absorbibles o sustitutos de grasas aceitosas indigeribles.
ARP990104054A 1998-08-14 1999-08-12 Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento AR035001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12

Publications (1)

Publication Number Publication Date
AR035001A1 true AR035001A1 (es) 2004-04-14

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104054A AR035001A1 (es) 1998-08-14 1999-08-12 Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento

Country Status (19)

Country Link
US (1) US6358522B1 (es)
EP (1) EP1105122B1 (es)
JP (1) JP3774118B2 (es)
KR (1) KR20010079635A (es)
CN (1) CN1170534C (es)
AR (1) AR035001A1 (es)
AT (1) ATE293970T1 (es)
AU (1) AU761351B2 (es)
BR (1) BR9912980B1 (es)
CA (1) CA2340056C (es)
CO (1) CO5130009A1 (es)
DE (1) DE69924999T2 (es)
DK (1) DK1105122T3 (es)
ES (1) ES2242413T3 (es)
MA (1) MA26671A1 (es)
PE (1) PE20000953A1 (es)
PT (1) PT1105122E (es)
TR (1) TR200100471T2 (es)
WO (1) WO2000009122A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
AU745697B2 (en) 1998-09-08 2002-03-28 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
IL153282A0 (en) 2000-06-27 2003-07-06 Hoffmann La Roche Method for preparing a pharmaceutical composition
AU2001289699B2 (en) * 2000-07-28 2006-06-01 Cheplapharm Arzneimittel Gmbh New pharmaceutical composition
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
BR0113101A (pt) 2000-08-09 2003-06-24 Hoffmann La Roche Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional
ATE403647T1 (de) 2000-10-16 2008-08-15 Hoffmann La Roche Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
ES2291374T3 (es) 2000-12-27 2008-03-01 F. Hoffmann-La Roche Ag Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c.
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
CN100376557C (zh) 2001-05-21 2008-03-26 霍夫曼-拉罗奇有限公司 作为神经肽y受体的配体的喹啉衍生物
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
RU2298002C2 (ru) 2002-02-04 2007-04-27 Ф. Хоффманн-Ля Рош Аг Производные хинолина в качестве антагонистов npy
MXPA04008379A (es) 2002-02-28 2004-11-26 Hoffmann La Roche Derivados de tiazol como antagonistas del receptor de neuropeptido y (npy).
DE60330764D1 (de) 2002-04-26 2010-02-11 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
EP1560816A1 (en) 2002-07-05 2005-08-10 F. Hoffmann-La Roche Ag Quinazoline derivatives
BR0313278A (pt) 2002-08-07 2005-07-05 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos
DK1539746T3 (da) 2002-09-12 2007-03-26 Hoffmann La Roche N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
ATE405560T1 (de) 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
MXPA06001570A (es) 2003-08-12 2006-05-15 Hoffmann La Roche Antagonistas del receptor de neuropeptido y (npy) 2-amino-5-benzoiltiazol.
EP1656374B1 (en) 2003-08-12 2009-03-11 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
EP1888585B1 (en) 2005-05-03 2011-06-29 F. Hoffmann-La Roche AG Tetracyclic azapyrazinoindolines as 5-ht2 ligands
EP1897558B1 (en) * 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
CN101243078A (zh) 2005-08-18 2008-08-13 霍夫曼-拉罗奇有限公司 噻唑基哌啶衍生物
EP1968967B1 (en) 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
AU2006319234B2 (en) 2005-11-30 2012-01-19 F. Hoffmann-La Roche Ag 1,5-substituted indol-2-yl amide derivatives
ES2342979T3 (es) 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.
DE602006010433D1 (de) 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
CA2631694A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
JP2009519293A (ja) 2005-12-16 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３レセプター調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
EP2032554A1 (en) 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
AU2008254214B2 (en) * 2007-05-16 2012-03-08 Buckman Laboratories International, Inc. Methods to control organic contaminants in fibers
AU2008280257A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[B]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
EP3471709A1 (en) * 2016-06-17 2019-04-24 The Procter & Gamble Company Soft chewable composition comprising psyllium
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
CN1170534C (zh) 2004-10-13
BR9912980A (pt) 2001-05-08
EP1105122A1 (en) 2001-06-13
CA2340056A1 (en) 2000-02-24
WO2000009122A1 (en) 2000-02-24
JP2002522491A (ja) 2002-07-23
ES2242413T3 (es) 2005-11-01
PT1105122E (pt) 2005-08-31
DE69924999D1 (de) 2005-06-02
AU761351B2 (en) 2003-06-05
TR200100471T2 (tr) 2001-07-23
EP1105122B1 (en) 2005-04-27
PE20000953A1 (es) 2000-09-26
JP3774118B2 (ja) 2006-05-10
AU5418599A (en) 2000-03-06
DK1105122T3 (da) 2005-08-08
US6358522B1 (en) 2002-03-19
ATE293970T1 (de) 2005-05-15
CA2340056C (en) 2007-01-09
KR20010079635A (ko) 2001-08-22
MA26671A1 (fr) 2004-12-20
DE69924999T2 (de) 2006-05-04
BR9912980B1 (pt) 2013-10-22
CN1312713A (zh) 2001-09-12
CO5130009A1 (es) 2002-02-27

Similar Documents

Publication Publication Date Title
AR035001A1 (es) Composiciones farmaceuticas de administracion oral, que contienen un inhibidor de lipasa gastrointestinal, el comprimido masticable y el uso de dichos compuestos para preparar un medicamento
US8853269B2 (en) Composition and method for treating infections and promoting intestinal health
ATE243030T1 (de) Orale zubereitung zur prophylaktischen/therapeutischen behandlung von helicobactor sp. infektionen
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
BR9611802A (pt) Composições farmacêuticas
AR035652A1 (es) Una composicion nutricional, util para combatir la infeccion en el tracto gastrointestinal causada por organismos tipo helicobacter, el uso de dicha composicion para la preparacion de medicamentos, o productos alimenticios y el procedimiento para preparar dicha composicion
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CN101835464A (zh) 抗疟疾药物组合物
KR970061244A (ko) 치매 치료용 약학 조성물
PT1221867E (pt) Composicao nutritivo compreendendo um precursor da anandamida
RU2004134573A (ru) Фармацевтическая композиция, включающая ингибитор липазы и глюкоманнан
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
KR970705988A (ko) 연골 조직의 이상에 기인하는 질환의 예방 또는 치료제(Preventive or remedy for diseases caused by abnormalities in cartilage tissues)
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
JP5795760B2 (ja) ジヒドロアルテミシニンを含む舌下スプレー用製剤
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
RU2006131758A (ru) Композиция для предупреждения простуды
AU763995B2 (en) Treatment of dyspepsia
BR0112830A (pt) Medicamento destinado especialmente a combater as disfunções sexuais
RU2010125505A (ru) Фармацевтический набор из эмульсии типа "масло в воде" и твердой композиции
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
KR980700083A (ko) 골다공증 치료 주기용 키트(KIT for Osteoporosis Treatment Cycle)
CO6241106A2 (es) Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal

Legal Events

Date Code Title Description
FG Grant, registration
FC Refusal